IL2 and melanoma: The first TIL therapy study by Rosenberg et al. (2011) emphasizes that despite prior treatments with high-dose IL-2, 5 out of 11 heavily pretreated melanoma patients achieved either complete or partial responses (CR + PR) with adoptive T cell transfer.